Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2752716,plasma concentrations,"At steady-state, mean plasma concentrations of lomefloxacin ranged from a maximum of 4.86 micrograms/ml to a minimum of 1.47 micrograms/ml.",Pharmacokinetics and safety of lomefloxacin following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752716/),[μg] / [ml],4.86,1931,DB00978,Lomefloxacin
,2752716,plasma concentrations,"At steady-state, mean plasma concentrations of lomefloxacin ranged from a maximum of 4.86 micrograms/ml to a minimum of 1.47 micrograms/ml.",Pharmacokinetics and safety of lomefloxacin following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752716/),[μg] / [ml],1.47,1932,DB00978,Lomefloxacin
,2752716,time to maximum plasma concentration,Mean time to maximum plasma concentration on Day 14 was 1.23 hr in the morning and 3.81 hr in the evening.,Pharmacokinetics and safety of lomefloxacin following multiple doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752716/),h,1.23,1933,DB00978,Lomefloxacin
,2752716,time to maximum plasma concentration,Mean time to maximum plasma concentration on Day 14 was 1.23 hr in the morning and 3.81 hr in the evening.,Pharmacokinetics and safety of lomefloxacin following multiple doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752716/),h,3.81,1934,DB00978,Lomefloxacin
,2752716,Plasma half-life,Plasma half-life was approximately 8 hr.,Pharmacokinetics and safety of lomefloxacin following multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752716/),h,8,1935,DB00978,Lomefloxacin
,7625786,peak concentrations in plasma (Cmax),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.88,10775,DB00978,Lomefloxacin
,7625786,peak concentrations in plasma (Cmax),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.60,10776,DB00978,Lomefloxacin
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[μg] / [ml],2.60,10777,DB00978,Lomefloxacin
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[h·μg] / [ml],24.9,10778,DB00978,Lomefloxacin
,7625786,areas under the curves (AUC),"The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine.",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),[h·μg] / [ml],11.9,10779,DB00978,Lomefloxacin
,7625786,half-life,"The Cmax of lomefloxacin was not significantly higher than that of ciprofloxacin, but lomefloxacin's AUC reached twice that of ciprofloxacin because of its significantly longer half-life in plasma (6.68 +/- 1.94 as against 4.15 +/- 0.92 h, respectively, P < or = 0.01).",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),h,6.68,10780,DB00978,Lomefloxacin
,7625786,half-life,"The Cmax of lomefloxacin was not significantly higher than that of ciprofloxacin, but lomefloxacin's AUC reached twice that of ciprofloxacin because of its significantly longer half-life in plasma (6.68 +/- 1.94 as against 4.15 +/- 0.92 h, respectively, P < or = 0.01).",Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625786/),h,4.15,10781,DB00978,Lomefloxacin
,1316068,nonrenal clearance,The mean nonrenal clearance of lomefloxacin (approximately 32 mL/min/1.72 m2) was not influenced by renal function.,Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316068/),[ml] / [1.72·m2·min],32,20785,DB00978,Lomefloxacin
,1316068,plasma clearances,"The mean plasma clearances of lomefloxacin in healthy subjects and in a subgroup of patients with severe renal impairment (creatinine clearance 5-15 mL/min/1.73 m2) were 209 and 43 mL/min/1.73 m2, respectively.",Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316068/),[ml] / [1.73·m2·min],209,20786,DB00978,Lomefloxacin
,1316068,plasma clearances,"The mean plasma clearances of lomefloxacin in healthy subjects and in a subgroup of patients with severe renal impairment (creatinine clearance 5-15 mL/min/1.73 m2) were 209 and 43 mL/min/1.73 m2, respectively.",Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316068/),[ml] / [1.73·m2·min],43,20787,DB00978,Lomefloxacin
,1316068,elimination half-life,"The elimination half-life of lomefloxacin increased significantly with the degree of renal impairment, from 7.5 hours in normal subjects to 26.9 hours in subjects with severe renal impairment.",Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316068/),h,7.5,20788,DB00978,Lomefloxacin
,1316068,elimination half-life,"The elimination half-life of lomefloxacin increased significantly with the degree of renal impairment, from 7.5 hours in normal subjects to 26.9 hours in subjects with severe renal impairment.",Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316068/),h,26.9,20789,DB00978,Lomefloxacin
,20426751,flow rate,"The chromatographic separation was achieved on a Zorbax Eclipse XDB-C18 column (150 mm x 4.6 mm i.d.) connected to a Phenomenex C(18) column (4 mm x 3.0 mm i.d.) using a mixture of acetonitrile: 15 mM citrate buffer (pH 3) (23:77, v/v) as the mobile phase with isocratic system at a flow rate of 1 mL/min.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[ml] / [min],1,42476,DB00978,Lomefloxacin
,20426751,recovery,"The results of the validation parameters were: linearity range, 3-6000 ng/mL (R(2) = 0.9994); mean recovery, 100.48 %; limit of quantification, 5 ng/mL; limit of detection, 1 ng/mL; and intra- and inter-day precision less than 3.2% and 5.1%, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),%,100.48,42477,DB00978,Lomefloxacin
,20426751,limit of detection,"The results of the validation parameters were: linearity range, 3-6000 ng/mL (R(2) = 0.9994); mean recovery, 100.48 %; limit of quantification, 5 ng/mL; limit of detection, 1 ng/mL; and intra- and inter-day precision less than 3.2% and 5.1%, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[ng] / [ml],1,42478,DB00978,Lomefloxacin
,20426751,Peak serum concentrations,"Peak serum concentrations of non-pregnant and caesarean-sectioned women at the arterial port after the infusion were 4.95 +/- 1.50 and 1.56 +/- 0.16 microg/mL, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[μg] / [ml],4.95,42479,DB00978,Lomefloxacin
,20426751,Peak serum concentrations,"Peak serum concentrations of non-pregnant and caesarean-sectioned women at the arterial port after the infusion were 4.95 +/- 1.50 and 1.56 +/- 0.16 microg/mL, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[μg] / [ml],1.56,42480,DB00978,Lomefloxacin
,20426751,elimination half-life,"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),h,5.54,42481,DB00978,Lomefloxacin
,20426751,volume of distribution,"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),l,215.85,42482,DB00978,Lomefloxacin
,20426751,area under the concentration-time curve (AUC)(0-infinity),"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[h·μg] / [ml],49.95,42483,DB00978,Lomefloxacin
,20426751,area under the concentration-time curve (AUC)(0-infinity),"The mean elimination half-life, volume of distribution and calculated area under the concentration-time curve (AUC)(0-infinity) were 5.54 +/- 0.73 h, 65.58 +/- 6.30 L and 49.95 +/- 6.30 microg.h/mL for non-pregnant women and 3.50 +/- 0.37 h, 215.85 +/- 24.87 L and 10.53 +/- 0.66 microg.h/mL for caesarean-sectioned women, respectively.",Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20426751/),[h·μg] / [ml],10.53,42484,DB00978,Lomefloxacin
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,5.7,43650,DB00978,Lomefloxacin
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,6.2,43651,DB00978,Lomefloxacin
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,10.8,43652,DB00978,Lomefloxacin
,2393260,bronchial mucosal concentration,"The median concentration in serum was 2.5 micrograms/ml (range, 1.0 to 5 micrograms/ml), and the median bronchial mucosal concentration was 5.0 micrograms/g (range, 0.7 to 18.6 micrograms/g).",Concentrations of oral lomefloxacin in serum and bronchial mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393260/),[μg] / [g],5.0,49291,DB00978,Lomefloxacin
,2393260,percent penetration,"The median percent penetration was 177% (range, 69 to 541%).",Concentrations of oral lomefloxacin in serum and bronchial mucosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393260/),%,177,49292,DB00978,Lomefloxacin
,8213172,recovery,The recovery of lomefloxacin was 95 to 102%.,[Highperformance liquid chromatographic assay for lomefloxacin in plasma and its pharmacokinetics in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213172/),%,95 to 102,50100,DB00978,Lomefloxacin
,8213172,detection limit,The detection limit of the method is 25 ng/ml.,[Highperformance liquid chromatographic assay for lomefloxacin in plasma and its pharmacokinetics in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213172/),[ng] / [ml],25,50101,DB00978,Lomefloxacin
,8213172,t1/2,Mean t1/2 value was 5.5 h.,[Highperformance liquid chromatographic assay for lomefloxacin in plasma and its pharmacokinetics in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213172/),h,5.5,50102,DB00978,Lomefloxacin
,2907467,urinary,"The urinary and fecal recoveries of NY-198 were 76.3 +/- 1.3% and 21.0 +/- 0.1% of the dose (mean +/- SE, N = 3), respectively, after the iv administration of [14C]NY-198 as a 20 mg/kg dose.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),%,76.3,59596,DB00978,Lomefloxacin
,2907467,fecal recoveries,"The urinary and fecal recoveries of NY-198 were 76.3 +/- 1.3% and 21.0 +/- 0.1% of the dose (mean +/- SE, N = 3), respectively, after the iv administration of [14C]NY-198 as a 20 mg/kg dose.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),%,21.0,59597,DB00978,Lomefloxacin
,2907467,volume of distribution at steady state per body weight (Vdss/BW),Model-independent moment analysis of the serum concentration-time profile of [14C]NY-198 gave the volume of distribution at steady state per body weight (Vdss/BW) as 1150 ml/kg.,"Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg],1150,59598,DB00978,Lomefloxacin
,2907467,Intrinsic renal clearance (CLint.kd),"Intrinsic renal clearance (CLint.kd) and intrinsic hepatic clearance (CLint.lv) were estimated to be 7.68 ml/min/kg and 6.33 ml/min/kg, respectively, by the cumulative urinary recovery and the area under the curve of the serum concentration-time profile of NY-198 and the blood flow rate.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg·min],7.68,59599,DB00978,Lomefloxacin
,2907467,intrinsic hepatic clearance (CLint.lv),"Intrinsic renal clearance (CLint.kd) and intrinsic hepatic clearance (CLint.lv) were estimated to be 7.68 ml/min/kg and 6.33 ml/min/kg, respectively, by the cumulative urinary recovery and the area under the curve of the serum concentration-time profile of NY-198 and the blood flow rate.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),[ml] / [kg·min],6.33,59600,DB00978,Lomefloxacin
,2907467,Kp,"The Kp values of NY-198 ranged from 0.22 to 4.85 and were very similar to those for ofloxacin, being the highest in the disposing organs, kidneys and liver, the lowest in fat and brain, and modest in the other nondisposing organs.","Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907467/),,0.22 to 4.85,59601,DB00978,Lomefloxacin
,2393286,Total,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],58.02,65371,DB00978,Lomefloxacin
,2393286,Total,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],56.57,65372,DB00978,Lomefloxacin
,2393286,Total,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],54.07,65373,DB00978,Lomefloxacin
,2393286,clearance,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],58.02,65374,DB00978,Lomefloxacin
,2393286,clearance,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],56.57,65375,DB00978,Lomefloxacin
,2393286,clearance,"Total theophylline clearance remained unchanged before lomefloxacin treatment and after lomefloxacin single- and multiple-dose treatments (58.02, 56.57, 54.07 ml/min, respectively).",Influence of lomefloxacin on the pharmacokinetics of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393286/),[ml] / [min],54.07,65376,DB00978,Lomefloxacin
,26590007,IC50,"Further examination showed that MFLX was an uncompetitive inhibitor, with an IC50 value of 4.29 ± 1.29 mm.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),mm,4.29,66918,DB00978,Lomefloxacin
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],171,66919,DB00978,Lomefloxacin
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],244,66920,DB00978,Lomefloxacin
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],338,66921,DB00978,Lomefloxacin
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],399,66922,DB00978,Lomefloxacin
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,41.7,66923,DB00978,Lomefloxacin
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,49.2,66924,DB00978,Lomefloxacin
,3282749,bioavaila,"With the exception of norfloxacin, which is only 30 to 40% bioavailable from the oral route, the 4-quinolones are 80 to 100% bioavailable, absorption occurring within 1 to 3 hours.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,80 to 100,67687,DB00978,Lomefloxacin
greater,3282749,volumes of distribution,"The 4-quinolones are widely distributed throughout the body, with volumes of distribution greater than 1.5 L/kg.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),[l] / [kg],1.5,67688,DB00978,Lomefloxacin
less,3282749,Protein binding,Protein binding is less than 30% in most cases.,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,30,67689,DB00978,Lomefloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,3 and 5,67690,DB00978,Lomefloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,8 to 14,67691,DB00978,Lomefloxacin
,1316069,maximum plasma concentration (Cmax),The mean (+/- standard deviation) maximum plasma concentration (Cmax) in these patients was 3.9 +/- 1.20 micrograms/mL.,Pharmacokinetics of lomefloxacin in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316069/),[μg] / [ml],3.9,78564,DB00978,Lomefloxacin
,1316069,time to maximum serum concentration (Tmax),"The mean time to maximum serum concentration (Tmax) was 2.1 +/- 2.6 hours, and the mean elimination half-life (t1/2) was 9.16 +/- 1.93 hours.",Pharmacokinetics of lomefloxacin in patients with cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316069/),h,2.1,78565,DB00978,Lomefloxacin
,1316069,elimination half-life (t1/2),"The mean time to maximum serum concentration (Tmax) was 2.1 +/- 2.6 hours, and the mean elimination half-life (t1/2) was 9.16 +/- 1.93 hours.",Pharmacokinetics of lomefloxacin in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316069/),h,9.16,78566,DB00978,Lomefloxacin
,1316069,renal clearance,"Mean renal clearance was 88.9 +/- 38.0 mL/min/1.73 m2, and the mean nonrenal clearance was 61.6 +/- 19.0 mL/min/1.73 m2, which corresponded to 41% of the total body clearance.",Pharmacokinetics of lomefloxacin in patients with cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316069/),[ml] / [1.73·m2·min],88.9,78567,DB00978,Lomefloxacin
,1316069,nonrenal clearance,"Mean renal clearance was 88.9 +/- 38.0 mL/min/1.73 m2, and the mean nonrenal clearance was 61.6 +/- 19.0 mL/min/1.73 m2, which corresponded to 41% of the total body clearance.",Pharmacokinetics of lomefloxacin in patients with cirrhosis. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316069/),[ml] / [1.73·m2·min],61.6,78568,DB00978,Lomefloxacin
,10211868,"liver-plasma unbound concentration ratio, K(pu)","The liver-plasma unbound concentration ratio, K(pu), of GPFX (1.7) was also higher than that of LFLX (0.7).","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,1.7,88885,DB00978,Lomefloxacin
,10211868,"liver-plasma unbound concentration ratio, K(pu)","The liver-plasma unbound concentration ratio, K(pu), of GPFX (1.7) was also higher than that of LFLX (0.7).","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,0.7,88886,DB00978,Lomefloxacin
,10211868,bile-liver unbound concentration ratio,"The bile-liver unbound concentration ratio of GPFX and LFLX was approximately 6 and 3, respectively, and the biliary clearance based on the unbound liver concentration of GPFX was 1.8 times that of LFLX.","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,6,88887,DB00978,Lomefloxacin
,10211868,bile-liver unbound concentration ratio,"The bile-liver unbound concentration ratio of GPFX and LFLX was approximately 6 and 3, respectively, and the biliary clearance based on the unbound liver concentration of GPFX was 1.8 times that of LFLX.","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,3,88888,DB00978,Lomefloxacin
,2088191,half-lives,"Mean half-lives for groups 1, 2, 3, and 4 were 8.09, 9.11, 20.90, and 44.25 h, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),h,8.09,92279,DB00978,Lomefloxacin
,2088191,half-lives,"Mean half-lives for groups 1, 2, 3, and 4 were 8.09, 9.11, 20.90, and 44.25 h, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),h,9.11,92280,DB00978,Lomefloxacin
,2088191,half-lives,"Mean half-lives for groups 1, 2, 3, and 4 were 8.09, 9.11, 20.90, and 44.25 h, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),h,20.90,92281,DB00978,Lomefloxacin
,2088191,half-lives,"Mean half-lives for groups 1, 2, 3, and 4 were 8.09, 9.11, 20.90, and 44.25 h, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),h,44.25,92282,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean lomefloxacin excretion rates over 48 h were 60.7, 56.0, 29.1, and 1.0% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,60.7,92283,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean lomefloxacin excretion rates over 48 h were 60.7, 56.0, 29.1, and 1.0% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,56.0,92284,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean lomefloxacin excretion rates over 48 h were 60.7, 56.0, 29.1, and 1.0% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,29.1,92285,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean lomefloxacin excretion rates over 48 h were 60.7, 56.0, 29.1, and 1.0% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,1.0,92286,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean glucuronide excretion rates over 48 h were 7.8, 6.3, 10.0, and 0.6% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,7.8,92287,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean glucuronide excretion rates over 48 h were 7.8, 6.3, 10.0, and 0.6% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,6.3,92288,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean glucuronide excretion rates over 48 h were 7.8, 6.3, 10.0, and 0.6% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,10.0,92289,DB00978,Lomefloxacin
,2088191,excretion rates,"Mean glucuronide excretion rates over 48 h were 7.8, 6.3, 10.0, and 0.6% of the administered dose for groups 1, 2, 3, and 4, respectively.",Pharmacokinetics of lomefloxacin in renally compromised patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),%,0.6,92290,DB00978,Lomefloxacin
below,2088191,CL(CR),The lomefloxacin dose should be reduced to 200 mg/day as the CL(CR) falls below 30 ml/min/1.73 m2.,Pharmacokinetics of lomefloxacin in renally compromised patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088191/),[ml] / [1.73·m2·min],30,92291,DB00978,Lomefloxacin
,1374582,peak serum concentration,"The peak serum concentration of lomefloxacin was 2.5-10.0 micrograms/mL (mean, 5.2 +/- 1.9 micrograms/mL).",Penetration of lomefloxacin into human prostatic tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1374582/),[μg] / [ml],2.5-10.0,98776,DB00978,Lomefloxacin
,1374582,peak serum concentration,"The peak serum concentration of lomefloxacin was 2.5-10.0 micrograms/mL (mean, 5.2 +/- 1.9 micrograms/mL).",Penetration of lomefloxacin into human prostatic tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1374582/),[μg] / [ml],5.2,98777,DB00978,Lomefloxacin
,3214495,maximum concentration in serum (Cmax),"The mean maximum concentration in serum (Cmax) ranged from 1.11 to 7.46 micrograms/ml for the 100- to 800-mg doses, respectively, and the AUC increased proportionally with the dose.",Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214495/),[μg] / [ml],1.11,110768,DB00978,Lomefloxacin
,3214495,maximum concentration in serum (Cmax),"The mean maximum concentration in serum (Cmax) ranged from 1.11 to 7.46 micrograms/ml for the 100- to 800-mg doses, respectively, and the AUC increased proportionally with the dose.",Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214495/),[μg] / [ml],7,110769,DB00978,Lomefloxacin
,3214495,time to Cmax (Tmax),The mean time to Cmax (Tmax) values averaged 64.8 +/- 28.8 min.,Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214495/),min,64.8,110770,DB00978,Lomefloxacin
,3214495,elimination half-life,"The elimination half-life and plasma clearance averaged 7.7 +/- 0.52 h and 259 +/- 37 ml/min, respectively.",Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214495/),h,7.7,110771,DB00978,Lomefloxacin
,3214495,plasma clearance,"The elimination half-life and plasma clearance averaged 7.7 +/- 0.52 h and 259 +/- 37 ml/min, respectively.",Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214495/),[ml] / [min],259,110772,DB00978,Lomefloxacin
>,11233805,T/S,"Tissue penetration was higher than serum, with a T/S >2 in the prostatic capsule and seminal blister, and a T/S >1.6 in the adenomatous tissue, in both groups of patients.",The role of lomefloxacin in the treatment of chronic prostatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11233805/),,2,117225,DB00978,Lomefloxacin
>,11233805,T/S,"Tissue penetration was higher than serum, with a T/S >2 in the prostatic capsule and seminal blister, and a T/S >1.6 in the adenomatous tissue, in both groups of patients.",The role of lomefloxacin in the treatment of chronic prostatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11233805/),,1.6,117226,DB00978,Lomefloxacin
,1325892,elimination half-lives,"Their elimination half-lives are 6-10 hours and they have good oral absorption, excellent penetration into many tissues and fluids, and a better drug-interaction profile than other similar agents.",Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1325892/),h,6-10,118112,DB00978,Lomefloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB00978,Lomefloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB00978,Lomefloxacin
,1336948,maximum plasma lomefloxacin concentration,"The maximum plasma lomefloxacin concentration (4.5 +/- 1.8 mg/liter), the time of occurrence of the maximum concentration (1.7 +/- 1.6 h), and the apparent volume of distribution associated with the terminal phase (2.19 +/- 1.05 liter/kg) were comparable to the values reported for healthy, young volunteers.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),[mg] / [l],4.5,137259,DB00978,Lomefloxacin
,1336948,time of occurrence of the maximum concentration,"The maximum plasma lomefloxacin concentration (4.5 +/- 1.8 mg/liter), the time of occurrence of the maximum concentration (1.7 +/- 1.6 h), and the apparent volume of distribution associated with the terminal phase (2.19 +/- 1.05 liter/kg) were comparable to the values reported for healthy, young volunteers.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),h,1.7,137260,DB00978,Lomefloxacin
,1336948,apparent volume of distribution associated with the terminal phase,"The maximum plasma lomefloxacin concentration (4.5 +/- 1.8 mg/liter), the time of occurrence of the maximum concentration (1.7 +/- 1.6 h), and the apparent volume of distribution associated with the terminal phase (2.19 +/- 1.05 liter/kg) were comparable to the values reported for healthy, young volunteers.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),[l] / [kg],2.19,137261,DB00978,Lomefloxacin
,1336948,elimination half-life,"Compared with the data reported for young adults, the elimination half-life (12.7 +/- 4.67 h) was longer and the apparent total body clearance (132 +/- 36.6 ml/min/1.73 m2) was lower in middle-aged to elderly patients.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),h,12.7,137262,DB00978,Lomefloxacin
,1336948,apparent total body clearance,"Compared with the data reported for young adults, the elimination half-life (12.7 +/- 4.67 h) was longer and the apparent total body clearance (132 +/- 36.6 ml/min/1.73 m2) was lower in middle-aged to elderly patients.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),[ml] / [1.73·m2·min],132,137263,DB00978,Lomefloxacin
,1336948,renal clearance,"These differences were most likely attributable to age-related decreases in renal function, as evidenced by the lower lomefloxacin renal clearance (70.3 +/- 33.5 ml/min) in patients.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),[ml] / [min],70.3,137264,DB00978,Lomefloxacin
,1336948,peak lomefloxacin concentration,"The peak lomefloxacin concentration in purulent, expectorated sputum samples of 4.3 +/- 1.2 mg/liter occurred 3.1 +/- 1.7 h after dose administration and subsequently declined to 1.7 +/- 0.5 mg/liter at the end of the 24-h dosing interval.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),[mg] / [l],4.3,137265,DB00978,Lomefloxacin
,1336948,peak lomefloxacin concentration,"The peak lomefloxacin concentration in purulent, expectorated sputum samples of 4.3 +/- 1.2 mg/liter occurred 3.1 +/- 1.7 h after dose administration and subsequently declined to 1.7 +/- 0.5 mg/liter at the end of the 24-h dosing interval.",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),[mg] / [l],1.7,137266,DB00978,Lomefloxacin
,1336948,percent penetration,"The percent penetration into sputum, as assessed by comparing the area under the curve for sputum and plasma samples, was 120 +/- 39.8 (range, 70 to 185).",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),,120,137267,DB00978,Lomefloxacin
,1336948,area under the curve,"The percent penetration into sputum, as assessed by comparing the area under the curve for sputum and plasma samples, was 120 +/- 39.8 (range, 70 to 185).",Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336948/),,120,137268,DB00978,Lomefloxacin
less,2118324,MICs,Bacterial strains for which MICs were less than 0.5 microgram/ml were inhibited with both dosing schedules.,Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118324/),[μg] / [ml],0.5,137923,DB00978,Lomefloxacin
,8885126,recovery,The recovery of ofloxacin added to saliva was 96.9-101.2% with a coefficient of variation of < 2.9%.,Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885126/),%,96.9-101.2,141520,DB00978,Lomefloxacin
,8885126,maximum concentration,"The maximum concentration of saliva and serum ofloxacin was 513.3-2,053.0 ng/ml and 768.2-3,089.0 ng/ml for dose of 100 mg or 200 mg, respectively.",Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885126/),[ng] / [ml],"513.3-2,053.0",141521,DB00978,Lomefloxacin
,8885126,maximum concentration,"The maximum concentration of saliva and serum ofloxacin was 513.3-2,053.0 ng/ml and 768.2-3,089.0 ng/ml for dose of 100 mg or 200 mg, respectively.",Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885126/),[ng] / [ml],"768.2-3,089.0",141522,DB00978,Lomefloxacin
,8885126,AUC0-6,"The AUC0-6 was 1,736.8-6,519.9 ng/h/ml in saliva and 2,875.5-10,086.0 ng/h/ml in serum, respectively.",Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885126/),[ng] / [h·ml],"1,736.8-6,519.9",141523,DB00978,Lomefloxacin
,8885126,AUC0-6,"The AUC0-6 was 1,736.8-6,519.9 ng/h/ml in saliva and 2,875.5-10,086.0 ng/h/ml in serum, respectively.",Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885126/),[ng] / [h·ml],"2,875.5-10,086.0",141524,DB00978,Lomefloxacin
,8885126,saliva versus serum concentration ratio,The saliva versus serum concentration ratio was 0.4-0.7 for doses of 100 and 200 mg.,Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885126/),,0.4-0.7,141525,DB00978,Lomefloxacin
,1316064,peak plasma,"The peak plasma and bone (subchondral bone from femoral head) concentrations reached approximately 4.0 micrograms/mL at 2 hours post-dose and 3.0 micrograms/mL at 3 hours post-dose, respectively.",Lomefloxacin concentrations in bone after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316064/),[μg] / [ml],4.0,148271,DB00978,Lomefloxacin
,1316064,bone,"The peak plasma and bone (subchondral bone from femoral head) concentrations reached approximately 4.0 micrograms/mL at 2 hours post-dose and 3.0 micrograms/mL at 3 hours post-dose, respectively.",Lomefloxacin concentrations in bone after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316064/),[μg] / [ml],4.0,148272,DB00978,Lomefloxacin
,1316064,bone,"The peak plasma and bone (subchondral bone from femoral head) concentrations reached approximately 4.0 micrograms/mL at 2 hours post-dose and 3.0 micrograms/mL at 3 hours post-dose, respectively.",Lomefloxacin concentrations in bone after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316064/),[μg] / [ml],3.0,148273,DB00978,Lomefloxacin
,1316064,concentrations,"The peak plasma and bone (subchondral bone from femoral head) concentrations reached approximately 4.0 micrograms/mL at 2 hours post-dose and 3.0 micrograms/mL at 3 hours post-dose, respectively.",Lomefloxacin concentrations in bone after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316064/),[μg] / [ml],3.0,148274,DB00978,Lomefloxacin
greater,1316064,bone-to-plasma ratio,Two hours after dosing the average bone-to-plasma ratio was greater than 0.6.,Lomefloxacin concentrations in bone after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316064/),,0.6,148275,DB00978,Lomefloxacin
,1885423,peak serum concentrations,In a volunteer pharmacokinetic study mean peak serum concentrations of lomefloxacin of 7.19 mg/l were obtained 1.5 h after an oral dose of 400 mg.,Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885423/),[mg] / [l],7.19,151631,DB00978,Lomefloxacin
,1885423,Urinary excretion,Urinary excretion was 34% in 6 h and 63% in 24 h and the mean peak concentration was 699 mg/l.,Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885423/),%,34,151632,DB00978,Lomefloxacin
,1885423,Urinary excretion,Urinary excretion was 34% in 6 h and 63% in 24 h and the mean peak concentration was 699 mg/l.,Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885423/),%,63,151633,DB00978,Lomefloxacin
,1885423,peak concentration,Urinary excretion was 34% in 6 h and 63% in 24 h and the mean peak concentration was 699 mg/l.,Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1885423/),[mg] / [l],699,151634,DB00978,Lomefloxacin
,2207304,Cmax,Mean Cmax values (0.92 micrograms ml-1 to 6.99 micrograms ml-1) increased linearly with dose.,Pharmacokinetics and safety of single oral doses of lomefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),[μg] / [ml],0.92,154026,DB00978,Lomefloxacin
,2207304,Cmax,Mean Cmax values (0.92 micrograms ml-1 to 6.99 micrograms ml-1) increased linearly with dose.,Pharmacokinetics and safety of single oral doses of lomefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),[μg] / [ml],6.99,154027,DB00978,Lomefloxacin
,2207304,tmax,"Mean tmax averaged 1.13 +/- 0.5 h and mean t1/2, 7.8 +/- 1.0 h over all doses.",Pharmacokinetics and safety of single oral doses of lomefloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),h,1.13,154028,DB00978,Lomefloxacin
,2207304,t1/2,"Mean tmax averaged 1.13 +/- 0.5 h and mean t1/2, 7.8 +/- 1.0 h over all doses.",Pharmacokinetics and safety of single oral doses of lomefloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),h,7.8,154029,DB00978,Lomefloxacin
,2207304,urinary concentrations,Mean urinary concentrations during the first 4 h postdosing ranged from 79 to 454 micrograms ml-1.,Pharmacokinetics and safety of single oral doses of lomefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),[μg] / [ml],79 to 454,154030,DB00978,Lomefloxacin
,2207304,"Maximum urinary excretion rate, Rmax","Maximum urinary excretion rate, Rmax, ranged from 5.84 mg h-1 to 34.90 mg h-1.",Pharmacokinetics and safety of single oral doses of lomefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),[mg] / [h],5.84,154031,DB00978,Lomefloxacin
,2207304,"Maximum urinary excretion rate, Rmax","Maximum urinary excretion rate, Rmax, ranged from 5.84 mg h-1 to 34.90 mg h-1.",Pharmacokinetics and safety of single oral doses of lomefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),[mg] / [h],34.90,154032,DB00978,Lomefloxacin
,2207304,elimination half-life,Lomefloxacin is rapidly absorbed with an elimination half-life of approximately 8 h.,Pharmacokinetics and safety of single oral doses of lomefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207304/),h,8,154033,DB00978,Lomefloxacin
,12408886,limit of detection (LOD),The limit of detection (LOD) for the method was 50 pg/ml based on a signal to noise ratio of 3.,Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408886/),[pg] / [ml],50,157308,DB00978,Lomefloxacin
,12408886,signal to noise ratio,The limit of detection (LOD) for the method was 50 pg/ml based on a signal to noise ratio of 3.,Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408886/),,3,157309,DB00978,Lomefloxacin
,1663107,peak serum concentration,The mean (+/- S.D.) peak serum concentration of lomefloxacin on the first day was 4.8 mg/l (+/- 1.5) observed at a mean of 156 min (+/- 88) and on the final day was 6.3 mg/l (+/- 2.5) at a mean of 119 min (+/- 68).,The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663107/),[mg] / [l],4.8,190603,DB00978,Lomefloxacin
,1663107,peak serum concentration,The mean (+/- S.D.) peak serum concentration of lomefloxacin on the first day was 4.8 mg/l (+/- 1.5) observed at a mean of 156 min (+/- 88) and on the final day was 6.3 mg/l (+/- 2.5) at a mean of 119 min (+/- 68).,The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663107/),[mg] / [l],6.3,190604,DB00978,Lomefloxacin
,1663107,serum half-life,The mean serum half-life on the first day was 10.0 h (+/- 2.8) and on the final day 10.3 h (+/- 2.5).,The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663107/),h,10.0,190605,DB00978,Lomefloxacin
,1663107,serum half-life,The mean serum half-life on the first day was 10.0 h (+/- 2.8) and on the final day 10.3 h (+/- 2.5).,The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663107/),h,10.3,190606,DB00978,Lomefloxacin
,8067740,MIC for 90%,"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200513,DB00978,Lomefloxacin
,8067740,MIC90],"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200514,DB00978,Lomefloxacin
,8067740,MIC90,"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200515,DB00978,Lomefloxacin
,8067740,MIC90,"A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],4.0,200516,DB00978,Lomefloxacin
>,8067740,MIC90,"A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],128,200517,DB00978,Lomefloxacin
,8067740,MIC90,"A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.06,200518,DB00978,Lomefloxacin
< or =,8067740,MIC90,"A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.03,200519,DB00978,Lomefloxacin
,8067740,MIC90,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],4.0,200520,DB00978,Lomefloxacin
,8067740,MIC90,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],2.0,200521,DB00978,Lomefloxacin
,8067740,MIC90s,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200522,DB00978,Lomefloxacin
,8067740,MIC90s,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.5,200523,DB00978,Lomefloxacin
,8067740,MIC90,"Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],2.0,200524,DB00978,Lomefloxacin
,8067740,MIC90,"Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],16,200525,DB00978,Lomefloxacin
,2498102,peak serum level,The mean peak serum level was 4.9 mg/l at a mean time of 0.8 h.,Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498102/),[mg] / [l],4.9,202442,DB00978,Lomefloxacin
,2498102,mean time,The mean peak serum level was 4.9 mg/l at a mean time of 0.8 h.,Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498102/),h,0.8,202443,DB00978,Lomefloxacin
,2498102,serum elimination half-life,The mean serum elimination half-life was 6.2 h.,Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498102/),h,6.2,202444,DB00978,Lomefloxacin
,2498102,maximum inflammatory fluid level,The mean maximum inflammatory fluid level attained was 3.2 mg/l at 2.7 h.,Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498102/),[mg] / [l],3.2,202445,DB00978,Lomefloxacin
,2327756,peak level,"In subjects with normal renal function, the peak level in plasma averaged 3.5 +/- 0.9 micrograms/ml (mean +/- standard deviation) and was obtained at 1.3 +/- 0.9 h.",Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),[μg] / [ml],3.5,205866,DB00978,Lomefloxacin
,2327756,absorption rate constant,The absorption rate constant was 3.8 +/- 1.6 h-1.,Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),1/[h],3.8,205867,DB00978,Lomefloxacin
,2327756,terminal half-life,The terminal half-life was 7.77 +/- 0.95 h.,Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),h,7.77,205868,DB00978,Lomefloxacin
,2327756,apparent volume of distribution,The apparent volume of distribution was 2.54 +/- 0.66 liters/kg.,Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),[l] / [kg],2.54,205869,DB00978,Lomefloxacin
,2327756,Total body,"Total body and renal clearances were 259 +/- 83 and 200 +/- 55 ml/min per 1.73 m2, respectively.",Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),[ml] / [1.73·m2·min],259,205870,DB00978,Lomefloxacin
,2327756,renal clearances,"Total body and renal clearances were 259 +/- 83 and 200 +/- 55 ml/min per 1.73 m2, respectively.",Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),[ml] / [1.73·m2·min],200,205871,DB00978,Lomefloxacin
,2327756,percentage of the,The percentage of the dose recovered unchanged in 48-h urine was 80.6 +/- 2.8.,Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),,80.6,205872,DB00978,Lomefloxacin
,2327756,terminal half-life,"In uremic patients, the terminal half-life increased in relation to the degree of renal failure: from 8 h in normal subjects to 38 h in severely uremic patients (glomerular filtration rate, less than 10 ml/min).",Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),h,8,205873,DB00978,Lomefloxacin
,2327756,terminal half-life,"In uremic patients, the terminal half-life increased in relation to the degree of renal failure: from 8 h in normal subjects to 38 h in severely uremic patients (glomerular filtration rate, less than 10 ml/min).",Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),h,38,205874,DB00978,Lomefloxacin
,2327756,clearance,The dialysis clearance of lomefloxacin was 54 +/- 13 ml/min.,Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327756/),[ml] / [min],54,205875,DB00978,Lomefloxacin
,2069371,maximum caffeine concentrations,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[μg] / [ml],4.35,208657,DB00978,Lomefloxacin
,2069371,maximum caffeine concentrations,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[μg] / [ml],4.07,208658,DB00978,Lomefloxacin
,2069371,areas under the concentration-time curve from time zero to 24 h at steady state,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[h·μg] / [ml],30.3,208659,DB00978,Lomefloxacin
,2069371,areas under the concentration-time curve from time zero to 24 h at steady state,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[h·μg] / [ml],29.7,208660,DB00978,Lomefloxacin
,2069371,elimination half-lives,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),h,4.8,208661,DB00978,Lomefloxacin
,2069371,elimination half-lives,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),h,4.8,208662,DB00978,Lomefloxacin
,12408922,R(F),The peak for LMF resolved at R(F) of 0.40+/-0.02.,Determination of bioequivalence of lomefloxacin tablets using urinary excretion data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408922/),,0.40,211989,DB00978,Lomefloxacin
,12408922,limit of,"The limit of detection and limit of quantification for LMF in urine were found to be 20 and 50 microgram/ml, respectively.",Determination of bioequivalence of lomefloxacin tablets using urinary excretion data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408922/),[μg] / [ml],20,211990,DB00978,Lomefloxacin
,12408922,limit of quantification,"The limit of detection and limit of quantification for LMF in urine were found to be 20 and 50 microgram/ml, respectively.",Determination of bioequivalence of lomefloxacin tablets using urinary excretion data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408922/),[μg] / [ml],50,211991,DB00978,Lomefloxacin
,12408922,recovery,The average recovery of LMF from urine was 91.93%.,Determination of bioequivalence of lomefloxacin tablets using urinary excretion data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408922/),%,91.93,211992,DB00978,Lomefloxacin
,12408922,cumulative amounts,"The average cumulative amounts of LMF excreted in urine after administration of Formulation R and Formulation T were found to be 321.60 mg (80.40% of dose) and 296.51 mg (74.13% of dose), respectively.",Determination of bioequivalence of lomefloxacin tablets using urinary excretion data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408922/),mg,321.60,211993,DB00978,Lomefloxacin
,12408922,cumulative amounts,"The average cumulative amounts of LMF excreted in urine after administration of Formulation R and Formulation T were found to be 321.60 mg (80.40% of dose) and 296.51 mg (74.13% of dose), respectively.",Determination of bioequivalence of lomefloxacin tablets using urinary excretion data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408922/),mg,296.51,211994,DB00978,Lomefloxacin
,2675751,half-life,"There was a slight increase in the theophylline half-life from 6.72 +/- 1.63 to 7.02 +/- 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant.",Effect of lomefloxacin on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675751/),h,6.72,231707,DB00978,Lomefloxacin
,2675751,half-life,"There was a slight increase in the theophylline half-life from 6.72 +/- 1.63 to 7.02 +/- 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant.",Effect of lomefloxacin on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2675751/),h,7.02,231708,DB00978,Lomefloxacin
,8237402,peak levels,The peak levels in plasma averaged 6.0 +/- 1.3 and 5.9 +/- 1.0 micrograms.,Pharmacokinetics and relative bioavailability of lomefloxacin preparations in 10 healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237402/),μg,6.0,241381,DB00978,Lomefloxacin
,8237402,peak levels,The peak levels in plasma averaged 6.0 +/- 1.3 and 5.9 +/- 1.0 micrograms.,Pharmacokinetics and relative bioavailability of lomefloxacin preparations in 10 healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237402/),μg,5.9,241382,DB00978,Lomefloxacin
,8237402,areas under the drug concentration curves,"ml-1 at 1.3 +/- 0.4 and 1.2 +/- 0.4 h, and the areas under the drug concentration curves were 43 +/- 15 and 44 +/- 13 h.micrograms.",Pharmacokinetics and relative bioavailability of lomefloxacin preparations in 10 healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237402/),h·μg,43,241383,DB00978,Lomefloxacin
,8237402,areas under the drug concentration curves,"ml-1 at 1.3 +/- 0.4 and 1.2 +/- 0.4 h, and the areas under the drug concentration curves were 43 +/- 15 and 44 +/- 13 h.micrograms.",Pharmacokinetics and relative bioavailability of lomefloxacin preparations in 10 healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237402/),h·μg,44,241384,DB00978,Lomefloxacin
,8741334,maximum concentration (Cmax),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],0.80,242329,DB00978,Lomefloxacin
,8741334,maximum concentration (Cmax),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],1.20,242330,DB00978,Lomefloxacin
,8741334,elimination half time (t1/2),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,130,242331,DB00978,Lomefloxacin
,8741334,elimination half time (t1/2),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,96,242332,DB00978,Lomefloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],2.06,242333,DB00978,Lomefloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],1.89,242334,DB00978,Lomefloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],0.16,242335,DB00978,Lomefloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],0.62,242336,DB00978,Lomefloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,225,242337,DB00978,Lomefloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,295,242338,DB00978,Lomefloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,188,242339,DB00978,Lomefloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,175,242340,DB00978,Lomefloxacin
,8741334,ratio of aqueous humour/serum concentration,The ratio of aqueous humour/serum concentration of NFLX and LFLX was 7.8 and 35.3% 4 hrs after oral administration.,[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),,7,242341,DB00978,Lomefloxacin
,8741334,ratio of aqueous humour/serum concentration,The ratio of aqueous humour/serum concentration of NFLX and LFLX was 7.8 and 35.3% 4 hrs after oral administration.,[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),,35,242342,DB00978,Lomefloxacin
,2088193,Concentrations,Concentrations in serum during the perioperative period declined from 3.1 +/- 1.0 mg/liter (mean +/- standard deviation) at 1 h postdose to 2.3 +/- 0.7 mg/liter at 6 h postdose.,Intraprostatic distribution of lomefloxacin following multiple-dose administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088193/),[mg] / [l],3.1,245136,DB00978,Lomefloxacin
,2088193,Concentrations,Concentrations in serum during the perioperative period declined from 3.1 +/- 1.0 mg/liter (mean +/- standard deviation) at 1 h postdose to 2.3 +/- 0.7 mg/liter at 6 h postdose.,Intraprostatic distribution of lomefloxacin following multiple-dose administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088193/),[mg] / [l],2.3,245137,DB00978,Lomefloxacin
,2088193,time of tissue extraction,The time of tissue extraction ranged from 0.1 to 7.1 h postdose.,Intraprostatic distribution of lomefloxacin following multiple-dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088193/),h,0.1 to 7.1,245138,DB00978,Lomefloxacin
,2088193,concentrations,"Intraoperative serum lomefloxacin concentrations ranged from 0.5 to 4.8 (median, 2.4) mg/liter, while prostate tissue concentrations ranged from 1.1 to 10.1 (median, 5.4) mg/kg of tissue for the central zone and 0.9 to 6.5 (median, 5.2) mg/kg for the peripheral zone.",Intraprostatic distribution of lomefloxacin following multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088193/),,0.5 to 4.8,245139,DB00978,Lomefloxacin
,2088193,concentrations,"Intraoperative serum lomefloxacin concentrations ranged from 0.5 to 4.8 (median, 2.4) mg/liter, while prostate tissue concentrations ranged from 1.1 to 10.1 (median, 5.4) mg/kg of tissue for the central zone and 0.9 to 6.5 (median, 5.2) mg/kg for the peripheral zone.",Intraprostatic distribution of lomefloxacin following multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088193/),,2,245140,DB00978,Lomefloxacin
,2088193,prostate tissue concentrations,"Intraoperative serum lomefloxacin concentrations ranged from 0.5 to 4.8 (median, 2.4) mg/liter, while prostate tissue concentrations ranged from 1.1 to 10.1 (median, 5.4) mg/kg of tissue for the central zone and 0.9 to 6.5 (median, 5.2) mg/kg for the peripheral zone.",Intraprostatic distribution of lomefloxacin following multiple-dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088193/),[mg] / [kg],1.1 to 10.1,245141,DB00978,Lomefloxacin
,2088193,prostate tissue concentrations,"Intraoperative serum lomefloxacin concentrations ranged from 0.5 to 4.8 (median, 2.4) mg/liter, while prostate tissue concentrations ranged from 1.1 to 10.1 (median, 5.4) mg/kg of tissue for the central zone and 0.9 to 6.5 (median, 5.2) mg/kg for the peripheral zone.",Intraprostatic distribution of lomefloxacin following multiple-dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088193/),[mg] / [kg],5.4,245142,DB00978,Lomefloxacin
,1316066,Elimination half-lives,Elimination half-lives of 7-8 hours were found for all dosage regimens.,Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316066/),h,7-8,247442,DB00978,Lomefloxacin
,1316066,peak plasma concentration,"A 400 mg oral dose provided a mean peak plasma concentration of 3.43 micrograms/mL, and trough concentrations at steady state that were above the minimum inhibitory concentration for 90% (MIC90) of most common Enterobacteriaceae.",Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316066/),[μg] / [ml],3.43,247443,DB00978,Lomefloxacin
,2327750,maximum concentration of drug in serum,"After 400 mg of lomefloxacin was given once daily, no significant modification in the pharmacokinetic parameters was noted between the first and the fifth dose (maximum concentration of drug in serum, about 4 mg/liter; elimination half-life, about 6.3 h).",Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327750/),[mg] / [l],4,252599,DB00978,Lomefloxacin
,2327750,elimination half-life,"After 400 mg of lomefloxacin was given once daily, no significant modification in the pharmacokinetic parameters was noted between the first and the fifth dose (maximum concentration of drug in serum, about 4 mg/liter; elimination half-life, about 6.3 h).",Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327750/),h,6.3,252600,DB00978,Lomefloxacin
,2327750,minimum concentration,"After a dose of 200 mg every 12 h, a significant increase in the minimum concentration of drug in serum (0.49 +/- 0.1 and 0.72 +/- 0.2 mg/litter at days 1 and 5, respectively) and the area under the concentration-time curve (about 20%) was noted.",Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327750/),[mg] / [litter],0.49,252601,DB00978,Lomefloxacin
,2327750,minimum concentration,"After a dose of 200 mg every 12 h, a significant increase in the minimum concentration of drug in serum (0.49 +/- 0.1 and 0.72 +/- 0.2 mg/litter at days 1 and 5, respectively) and the area under the concentration-time curve (about 20%) was noted.",Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327750/),[mg] / [litter],0.72,252602,DB00978,Lomefloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],3.19 x 10(4),263673,DB00978,Lomefloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],1.21 x 10(5),263674,DB00978,Lomefloxacin
,3190181,peak level,"The mean peak level in serum, 4.7 micrograms/ml, was attained within 1 h of administration.",Pharmacokinetics and tissue penetration of orally administered lomefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190181/),[μg] / [ml],4.7,265663,DB00978,Lomefloxacin
,3190181,elimination half-life from serum,The mean elimination half-life from serum was 7 h.,Pharmacokinetics and tissue penetration of orally administered lomefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190181/),h,7,265664,DB00978,Lomefloxacin
,3190181,peak level,"Inflammatory fluid was penetrated rapidly, with a mean peak level of 3.5 micrograms/ml occurring after 2.7 h.",Pharmacokinetics and tissue penetration of orally administered lomefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190181/),[μg] / [ml],3.5,265665,DB00978,Lomefloxacin
,10609773,Cmax,Lomefloxacin showed a Cmax of 1.62 microg/ml at the Tmax of 1 hr whereas ciprofloxacin showed a Cmax of 102.8 ngs/ml at the Tmax of 1 hr.,Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609773/),[μg] / [ml],1.62,273443,DB00978,Lomefloxacin
,10609773,Tmax,Lomefloxacin showed a Cmax of 1.62 microg/ml at the Tmax of 1 hr whereas ciprofloxacin showed a Cmax of 102.8 ngs/ml at the Tmax of 1 hr.,Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609773/),h,1,273444,DB00978,Lomefloxacin
,10609773,Cmax,Lomefloxacin showed a Cmax of 1.62 microg/ml at the Tmax of 1 hr whereas ciprofloxacin showed a Cmax of 102.8 ngs/ml at the Tmax of 1 hr.,Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10609773/),[ngs] / [ml],102.8,273445,DB00978,Lomefloxacin
